Literature DB >> 19914721

Intratumoral IL-7 delivery by mesenchymal stromal cells potentiates IFNgamma-transduced tumor cell immunotherapy of experimental glioma.

Salina Gunnarsson1, Daniel Bexell, Andreas Svensson, Peter Siesjö, Anna Darabi, Johan Bengzon.   

Abstract

The present study reports regression of pre-established experimental rat gliomas as a result of combining peripheral immunization using interferon gamma (IFNgamma) transduced autologous tumor cells with local intratumoral delivery of interleukin 7 (IL-7) by mesenchymal stromal cells. IL-7 alone significantly decreased the tumor area and this effect was enhanced with IFNgamma immunization. A higher density of intratumoral T-cells was observed in animals receiving combined therapies compared to rats receiving either cytokine alone suggesting that the therapeutic effect is dependent on a T-cell response. Copyright 2009 Elsevier B.V. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19914721     DOI: 10.1016/j.jneuroim.2009.10.017

Source DB:  PubMed          Journal:  J Neuroimmunol        ISSN: 0165-5728            Impact factor:   3.478


  21 in total

Review 1.  Engineering antiphagocytic biomimetic drug carriers.

Authors:  Alicia Sawdon; Ching-An Peng
Journal:  Ther Deliv       Date:  2013-07

Review 2.  Mesenchymal stem cells at the intersection of cell and gene therapy.

Authors:  Timothy J Myers; Froilan Granero-Molto; Lara Longobardi; Tieshi Li; Yun Yan; Anna Spagnoli
Journal:  Expert Opin Biol Ther       Date:  2010-12       Impact factor: 4.388

3.  Mesenchymal stem cell-mediated cancer therapy: A dual-targeted strategy of personalized medicine.

Authors:  Xu-Yong Sun; Jiang Nong; Ke Qin; Garth L Warnock; Long-Jun Dai
Journal:  World J Stem Cells       Date:  2011-11-26       Impact factor: 5.326

Review 4.  Mesenchymal stem cells engineered for cancer therapy.

Authors:  Khalid Shah
Journal:  Adv Drug Deliv Rev       Date:  2011-06-29       Impact factor: 15.470

5.  Use of genetically engineered stem cells for glioma therapy.

Authors:  Hiroki Namba; Hiroshi Kawaji; Tomohiro Yamasaki
Journal:  Oncol Lett       Date:  2015-11-04       Impact factor: 2.967

6.  Specific chemotaxis of magnetically labeled mesenchymal stem cells: implications for MRI of glioma.

Authors:  Margaret F Bennewitz; Kevin S Tang; Eleni A Markakis; Erik M Shapiro
Journal:  Mol Imaging Biol       Date:  2012-12       Impact factor: 3.488

Review 7.  Toward brain tumor gene therapy using multipotent mesenchymal stromal cell vectors.

Authors:  Daniel Bexell; Stefan Scheding; Johan Bengzon
Journal:  Mol Ther       Date:  2010-04-20       Impact factor: 11.454

Review 8.  Novel gamma-chain cytokines as candidate immune modulators in immune therapies for cancer.

Authors:  Natasha M Fewkes; Crystal L Mackall
Journal:  Cancer J       Date:  2010 Jul-Aug       Impact factor: 3.360

9.  Inhibitory effect of genetically engineered mesenchymal stem cells with Apoptin on hepatoma cells in vitro and in vivo.

Authors:  Jingsi Zhang; Lingling Hou; Xiaoyan Wu; Diandian Zhao; Ziling Wang; Honggang Hu; Yuanhui Fu; Jinsheng He
Journal:  Mol Cell Biochem       Date:  2016-05-03       Impact factor: 3.396

Review 10.  Mesenchymal stem cells as a vector for the inflammatory prostate microenvironment.

Authors:  W Nathaniel Brennen; Samuel R Denmeade; John T Isaacs
Journal:  Endocr Relat Cancer       Date:  2013-08-23       Impact factor: 5.678

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.